Valvular & structural heart disease
Four-year durability of the Myval balloon-expandable transcatheter aortic valve
Authors' conclusion
In a real-world cohort, 4-year outcomes with the balloon-expandable Myval series demonstrated acceptable valve durability, low haemodynamic deterioration, and comparable performance to contemporary TAVI systems.
Study context
- Population
- Patients with severe aortic stenosis who underwent transcatheter aortic valve implantation (TAVI) with the Myval series between December 2017 and April 2020from 9 institutions, all completed 4-year follow-up or were followed up until death
- Participants
- 366 patients
- Outcome
- Survival
- Follow-up
- 4 years
Main finding
As reported in the abstract
4-year survival rate
81.8%
Further findings
Residual ≥moderate aortic regurgitation
- Residual ≥moderate aortic regurgitation
- 9.2%
Bioprosthetic valve failure (BVF) (VARC-3)
- BVF criterion 1 (symptomatic valve failure)
- 3.3%
- No cases of BVF criteria 2 or 3
Haemodynamic valve deterioration (HVD) (VARC-3) · 4 years
- Stage 2 HVD
- 9.7%
- Stage 3 HVD
- 0.7%
Patient-prosthesis mismatch (PPM) (VARC-3) · 1 year
- Moderate PPM
- 3.6%
- Severe PPM
- 2.1%
Original publication
Four-year durability of the Myval balloon-expandable transcatheter aortic valve. EuroIntervention. Published 7 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →